Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administration

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2330-2337

  Conry, Robert M ^a   Khazaeli, Muhamad B ^a   Saleh, Mansoor N ^a   Allen, Karen O ^a   Barlow, Daunte L ^a   Moore, Susan E ^a   Craig, Dayle ^a   Arani, Ramin B ^a   Schlom, Jeffrey ^b   LoBuglio, Albert F ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKINE; INTERLEUKIN 2; VACCINIA VACCINE; VIRUS VECTOR;

ADENOCARCINOMA; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; FATIGUE; FEMALE; FEVER; HUMAN; INTRADERMAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION; VIRUS RECOMBINANT;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, VIRAL; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; VACCINIA VIRUS;

EID: 0032835614     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Thompson, J. A., Grunert, F., and Zimmermann, W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J. Clin. Lab. Anal., 5: 344-366, 1991.
2. Kaufman, H., Schlom, J., and Kantor, J. A recombinant vaccinia virus expressing human CEA. Int. J. Cancer, 48: 900-907, 1991.
3. Kantor, J., Irvine, K., Abrams, S., Kaufman, H., DiPoetro, J., and Schlom, J. Antitumor activity and immune responses induced by a recombinant CEA-vaccinia virus vaccine. J. Natl. Cancer Inst., 84: 1084-1091, 1992.
4. Kantor, J., Abrams, S., Snoy, P., Greiner, J., Kaufman, H., Eggensperger, D., and Schlom, J. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the CEA gene in a non-human primate. Cancer Res., 52: 6917-6925, 1992.
5. Hamilton J. M., Chen A. P., and Nguyen B. Phase I study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas. Proc. Am. Soc. Clin. Oncol., 13: 961, 1994.
6. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Ming, Z. Z., Hamilton, J. M., and Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
7. Conry, R. M., Saleh, M. N., Schlom, J., and LoBuglio, A. F. Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus vaccine in man. Proc. Am. Assoc. Cancer Res., 36: 2930, 1995.
8. Gritz, L., Destree, A., Cormier, N., Day, E., Stallard, V., Caiazzo, T., Mazzara, G., and Panicali, D. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J. Virol., 64: 5948-5957, 1990.
9. Conry, R. M., LoBuglio, A. F., Loechel, F., Moore, S. E., Sumerel, L. A., Barlow, D. L., and Curiel, D. T. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther., 2: 59-65, 1995.
10. Davis, L. S., Lipsky, P. E., and Bottomly, K. Measurement of human and murine interleukin 2 and interleukin 4. In: J. E. Colligan, A. M. Kruisbeck, D. H. Margulies, E. M. Shevach, and W. Strober (eds.), Current Protocols in Immunology, pp. 6.3.1-6.3.12. New York: Gene Publishing Associates and Wiley-Interscience, 1992.
11. Lane, J. M., Ruben, F. L., Neff, J. M., and Miller, J. D. Complications of smallpox vaccination, 1968. N. Engl. J. Med., 281: 1201-1208, 1969.
12. Schwartz, K., Bruckel, N., Schwaibold, H., von Kleist, S., and Grunert, F. Non-specific cross-reacting antigen: characterization of specific and cross-reacting epitopes. Mol. Immunol., 26: 467-475, 1989.
13. Matyas, G. R., Harris, D. T., Alving, C. R., Mastrangelo, M., Livinston, P. O., Schlom, J., Talmadge, J. E., Muderhwa, J., Richards, R. L., Glenn, G., and Spitler, L. E. Therapeutic autoimmunity: induction of antibodies to prostate specific antigen by Onco Vax-P™, a liposomebased vaccine for therapy of prostate cancer. J. Clin. Oncol., in press, 1999.
14. Foon, K. A., John, W. J., Chakraborty, M., Sherratt, A., Garrison, J., Flett, M., and Bhattacharya-Chatterjee, M. Clinical and immune response in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin. Cancer Res., 3: 1267-1276, 1997.
15. Hodge, J. W., McLaughlin, J. P., Abrams, S. L., Shupert, W. L., Schlom, J., and Kantor, J. A. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T cell responses and antitumor immunity. Cancer Res., 55: 3598-3603, 1995.
16. Akagi, J., Hodge, J. W., McLaughlin, J. P., Gritz, L., Mazzara, G., Kufe, D., Schlom, J., and Kantor, J. Therapeutic antitumor response after immunization with admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T cell costimulatory molecule B7. J. Immunother., 20: 38-47, 1997.
17. Hodge, J. W., McLaughlin, J. P., Kantor, J. A., and Schlom, J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T cell immunity and antitumor responses. Vaccine, 15: 759-768, 1997.
18. Etlinger, H. M., and Altenburger, W. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus. Vaccine, 9: 470-472, 1991.
19. Kundig, T. M., Kalberer, C. P., Hengartner, C. P., and Zinkemagel, R. M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine, 11: 1154-1158, 1993.